Your browser doesn't support javascript.
loading
Bicarbonate defective CFTR variants increase risk for chronic pancreatitis: A meta-analysis.
Berke, Gergo; Gede, Noémi; Szadai, Letícia; Ocskay, Klementina; Hegyi, Péter; Sahin-Tóth, Miklós; Hegyi, Eszter.
Afiliação
  • Berke G; Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
  • Gede N; Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
  • Szadai L; Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
  • Ocskay K; Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
  • Hegyi P; Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
  • Sahin-Tóth M; Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Hegyi E; Division of Pancreatic Diseases, Heart and Vascular Centre, Semmelweis University, Budapest, Hungary.
PLoS One ; 17(10): e0276397, 2022.
Article em En | MEDLINE | ID: mdl-36264955
INTRODUCTION: Cystic fibrosis transmembrane conductance regulator (CFTR) plays a central role in pancreatic ductal fluid secretion by mediating Cl- and HCO3- ion transport across the apical membrane. Severe CFTR mutations that diminish chloride conductance cause cystic fibrosis (CF) if both alleles are affected, whereas heterozygous carrier status increases risk for chronic pancreatitis (CP). It has been proposed that a subset of CFTR variants characterized by a selective bicarbonate conductance defect (CFTRBD) may be associated with CP but not CF. However, a rigorous genetic analysis of the presumed association has been lacking. AIMS: To investigate the role of heterozygous CFTRBD variants in CP by meta-analysis of published case-control studies. MATERIALS AND METHODS: A systematic search was conducted in the MEDLINE, Embase, Scopus, and CENTRAL databases for published studies that reported the CFTRBD variants p.R74Q, p.R75Q, p.R117H, p.R170H, p.L967S, p.L997F, p.D1152H, p.S1235R, and p.D1270N in CP patients and controls. RESULTS: Twenty-two studies were eligible for quantitative synthesis. Combined analysis of the 9 CFTRBD variants indicated enrichment in CP patients versus controls (OR = 2.31, 95% CI = 1.17-4.56). Individual analysis of CFTRBD variants revealed no association of p.R75Q with CP (OR = 1.12, 95% CI = 0.89-1.40), whereas variants p.R117H and p.L967S were significantly overrepresented in cases relative to controls (OR = 3.16, 95% CI = 1.94-5.14, and OR = 3.88, 95% CI = 1.32-11.47, respectively). The remaining 6 low-frequency variants gave inconclusive results when analyzed individually, however, their pooled analysis indicated association with CP (OR = 2.08, 95% CI = 1.38-3.13). CONCLUSION: Heterozygous CFTRBD variants, with the exception of p.R75Q, increase CP risk about 2-4-fold.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Regulador de Condutância Transmembrana em Fibrose Cística / Pancreatite Crônica Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Regulador de Condutância Transmembrana em Fibrose Cística / Pancreatite Crônica Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article